Medpage Today on MSN2d
FDA Adds Guillain-Barre Syndrome Warning to Two RSV VaccinesThe CDC recommends a single dose of any FDA-approved RSV vaccine for all adults ages 75 years and older, as well as for 60- ...
Findings from a postmarketing observational study showed an increased risk of GBS during the 42 days following vaccination.
The FDA is adding a warning about Guillain-Barré syndrome to the respiratory syncytial virus vaccines manufactured by GSK and ...
A post-marketing review by the FDA detected an increased risk of the autoimmune condition in patients inoculated with GSK’s ...
Rare Guillain-Barré Syndrome cases were found after ChAdOx1 vaccine in India; vigilance is urged despite vaccine’s overall safety.
The change was prompted by postmarketing observational studies that suggest an increased risk of GBS within 42 days of ...
On the other hand, if the FDA rejects Annexon's filing, Annexon may have to go back and revise its RWE study or even open a ...
Guillain-Barré syndrome (GBS) is an acute inflammatory neuropathy that can lead to severe weakness of the limbs, face, and respiratory muscles. Its pathophysiology involves autoantibodies that ...
Regulators say, however, the benefits of vaccination with Abrysvo and Arexvy in preventing respiratory syncytial virus ...
The study found that those treated with a combination of imlifidase and immunoglobulin saw their ability to walk restored in ...
To study the extent to which patients experience residual problems in daily functioning several years after having Guillain-Barré syndrome (GBS) a survey of 123 patients who had had Guillain-Barré ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback